repeat treatment with herceptin effective in 42% even after lapatinib failure

[Lani]

If at 1st you don't succeed, try , try, again!


Retreatment with trastuzumab (T)-based therapy in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) resistant to lapatinib (L)-based therapy.


Sub-category:
HER2+

Category:
Breast Cancer - HER2/ER

Meeting:
2011 ASCO Annual Meeting

Abstract No:
568

Citation:
J Clin Oncol 29: 2011 (suppl; abstr 568)



ASCO Annual Meeting!
Session: Breast Cancer - HER2/ER

Type: General Poster Session

Time: Monday June 6, 1:00 PM to 5:00 PM

Location: McCormick Place Hall A

Personalize your Annual Meeting experience with a suggested or customized itinerary!

Author(s): S. Gori, F. Montemurro, S. Spazzapan, G. Metro, J. Foglietta, G. Bisagni, A. Ferzi, R. R. Silva, T. Gamucci, M. Clavarezza, L. Stocchi, A. Fabi, F. Cognetti, E. Torrisi, D. Crivellari; Oncologia Medica, A.O. di Perugia, Perugia, Italy; Institute for Cancer Research and Treatment, Turin, Italy; National Cancer Institute, Aviano, Italy; Medical Oncology Department, Santa Maria della Misericordia Hospital, Perugia, Italy; Azienda Ospedaliera Perugia, Perugia, Italy; Division of Oncology, Arcispedale S. Maria Nuova, Reggio Emilia, Italy; Medicina II - Oncologia Medica, Ospedale Civile di Legnano, Legnano, Italy; Ospedale Profili, Fabriano, Italy; Medical Oncology Unit, ASL Frosinone, Frosinone, Italy; Don Calabria Hospital, Negrar, Italy; Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy; Regina Elena National Cancer Institute, Rome, Italy; CRO - National Cancer Institute, Aviano, Italy


Abstract Disclosures


Abstract:

Background: Preclinical data suggest that treatment with lapatinib may reinduce sensitivity to trastuzumab in HER2+ breast cancer cells (Scaltriti, Oncogene 2009;28:803). We evaluated the activity of retreatment with T-based therapy after L in HER2+ MBC pts. Methods: 69 HER2+ MBC pts retreated with T after L progression were identified using pharmacy records from 9 Italian Institutions (Jan 2007-Nov 2010). Response to T retreatment, post-T progression-free survival (PFS) and overall survival (OS) were evaluated. Results: Pts median age was 57 y (26-79); ECOG PS was 0-1 in 77% (53/69), 2 in 7% (5/69) and not registered for 16% (11/69) of the pts; 51 pts (74%) had visceral metastases and 16 (23%) brain metastases with or without visceral involvement. All pts were pretreated with both T- and L-based therapy for MBC, and 11 had also received adjuvant T. The median number of chemotherapeutic lines for MBC before L was 2 (range 0-8) including a median of 2 (0-6) T-based regimens. The median duration of L was 5.7 months (range 0.7-19.5). Retreatment with T was associated with a clinical benefit rate of 42%, including 1 CR (1.4%), 18 PRs (26%) and 10 SDs lasting ≥ 6 months (14%). The median duration of response was 8.1 months (95% C.I. 5.5-10.7). At a median follow up of 13 months, median PFS was 4.9 months (95% CI 4.2-5.6) and median OS 19.5 months (95%CI 14.0-25.0). Median OS was longer for pts experiencing clinical benefit (not reached vs 13.4 months for pts without CB, p= 0.002). CNS involvement was associated with lower median OS (17.3 months vs 23.3 months for patients without CNS involvement; p= 0.021). Conclusions: Retreatment with T-based therapy showed clinical benefit in 42% of pts progressing during L-based therapy. The prolonged OS observed in pts achieving a clinical benefit suggests that the sensitivity to trastuzumab re-induced by lapatinib in HER2+ breast cancer cells might have clinical implications that merit future prospective studies.

[pibikay]

Good news Lani for those to whom Laptnib does not work